Ion channels have recently attracted attention as potential mediators of skin disease.
101
Here, we explored the consequences of genetically encoded induction of the cell 7   143 KCa3.1, therefore, can be viewed as a possible driver of disease, and several 144 small molecule inhibitors for this therapeutically attractive target have been 145 developed and tested in pre-clinical animal models [35] [36] . The inhibitor, ICA-17043 146 (Senicapoc), initially intended for the treatment of sickle cell anemia, has been found 147 clinically safe [37] and is currently being considered for drug repurposing for stroke 148 and Alzheimer's disease, two conditions in which KCa3 343 particularly, in the epidermis, and a 46-fold overexpressing in the intestine (Fig 1 B) .
344 In bone marrow, brain, lung, skeletal muscle, spleen, KCa3.1-mRNA levels were 345 similar to untreated mice.
346
Patch-clamp electrophysiology studies in isolated keratinocytes revealed a 347 strong induction of KCa3. (Fig 1 C) . In fact, we saw a clearly distinguishable KCa3.1 current in only 1 of 5 cells 354 ( Fig S1A) .
355
We examined the KCa3.1-protein expression by immune histology (Fig 1 D) 356 and identified weak immune reactivity in the thin epidermal layer of untreated mice 357 and appreciable immune reactivity in the thicker epidermal layer of DOX-treated 358 mice (see following paragraphs).
359
Together, these findings demonstrate strong induction of KCa3.1-transgene 360 expression and function in the skin and, particularly, in the epidermis. 369 Histology (Fig 3 A to D) of neck skin showed moderate to severe hyperplasia 370 of the epidermis, affecting also the hair follicles, and substantial hyperkeratosis. In 371 the epidermis of the DOX-treated mice, we found foci of moderate intra-epidermal 372 edema (Fig 3 D) , similar to spongiosis, which is characteristic of eczematous 373 dermatitis [42]. The phenotype was completely reversible within 6 weeks when DOX 374 was removed after 9 days of treatment (see S1B Fig) . (Fig 3 F) , but at wound areas with substantial tissue destruction (S1E Fig) . 
Alterations of Cytokine Expression Profile in Skin

398
To shed light on the mechanisms, by which KCa3.1-induction in the 399 keratinocytes produced spongiosis and epidermal hyperplasia, we measured the 400 mRNA-expression of several pro-proliferative cytokines that are known to promote 401 keratinocyte proliferation in an auto-stimulatory or autacoid fashion [43] (Fig 4) . It is 402 worth mentioning that KCa3.1-KO and/or inhibition have been shown to reduce IL-β1
403 and TNFα levels in activated microglia after cerebral infarction [19] .
404
We found strongly increased mRNA expression of IL-β1 (60-fold), IL-23 (34-405 fold), IL-6 (33-fold), and TNFα (26-fold). Expression levels of HGF and TGFα as 406 well as a series of other cytokines and growth factors, of which some are expressed by 407 keratinocytes (amphiregulin, betacellulin, epiregulin, IL-2, IL-4, IL-25, IL-33, and 408 keratinocyte growth factor, for review see [43], were not significantly altered (Fig 4   409 A) . T-cell specific IL-17A and IL-17F mRNA expression was not detectable (data not 410 shown).
411
The induction of IL-β1, IL-23, and TNFα expression was particularly high in 412 the epidermal layer, although not statistically different from levels in the dermis. Yet, 413 these data demonstrate strong cytokine induction in keratinocytes (Fig 4 B) . 
424
As shown in Figure 5 A, we report that the Senicapoc treatment did not 425 prevent the pathological skin alterations, but significantly reduced intra-epidermal 426 edema by ≈60%, hyperplasia by ≈50%, as well as a trend in reduction of 427 hyperkeratosis and fibrosis.
428
Overall, this Senicapoc trial suggests that the skin pathology was caused largely by 429 the induced function of KCa3.1 and demonstrates that Senicapoc is able to reduce the 430 earliest strong alteration, i.e. intra-epidermal edema (Fig 3 C and D) , presumably by 431 blocking KCa.3.1-induced disturbances of epidermal water-salt homeostasis.
433
Considering cytokine levels in the skin (Fig 5 B) , Senicapoc significantly 434 reduced mRNA-expression levels of IL-β1 (≈-88%), IL-23 (≈-77%), as well as of IL- (Fig 1) .
465
The KCa3.1 induction in DOX-treated animals was specific for skin epidermis 466 as concluded from 800-fold overexpression. Concerning other tissues, we found a 467 much less pronounced 20-fold overexpression in the intestine (see below). 477 mRNA-expression of KCa3.1 (Fig 1 D) .
479
A major outcome of our study was that KCa3.1-induction produced visibly 480 piloerection, scaly skin patches, and intense scratching behavior that in turn gave rise 481 to bloody ulcerative lesions (Fig 2 and S1 Movie) . These symptoms are similar to 504 Therefore, intra-epidermal edema can be considered the starting point for the latter 505 alterations.
506
2) In addition to its function as a K + secreting channel, KCa3.1 activity is known to 507 produce strong membrane hyperpolarization, which in turn potentiates calcium-influx 508 enabling long-lasting elevations in [Ca 2+ ] I (for review see: [1, 36] known to regulate cytokine production in T cells, activated fibroblasts or smooth 513 muscle cells (for review see: [1] ). Accordingly, inhibition or genetic knockdown of 514 the channel has been reported to reduce IL-2 production by T cells [46-47] and IL-β1 515 and TNFα levels by microglia in ischemic stroke [19] . Here, we showed that the 516 reverse maneuver (induction) resulted in a higher expression of IL-β1, IL-23, and
517
TNFα in keratinocytes of the epidermis (Fig 5) . This keratinocyte cytokine production 518 may drive hyperplasia and hyperkeratosis in an auto-stimulatory fashion.
519
Considering the impressive magnitude of hyperplasia and hyperkeratosis 520 ( Figure 3 ), we speculate that this is a secondary and overshooting repair mechanism 521 in response to intra-epidermal edema and epidermal destabilization.
522
In summary, we provide first mechanistic evidence that KCa3.1 induction 523 produced skin pathology in-vivo by causing extracellular fluid accumulation and 524 epidermal destabilization as a primary event and secondary phenotypic switch to a 525 proliferative keratinocyte phenotype (PCNA-high, Fig 3E) , producing epidermal 526 hyperplasia.
528
It is worth mentioning that the selective KCa3.1-blocker Senicapoc 529 significantly reduced both the primary intra-epidermal edema and the subsequent 530 hyperplasia ( Fig 5) . The reduction in edema is somewhat reminiscent of the reported 531 reduction in in-vitro cyst formation by kidney cells from patients with autosomal-532 dominant polycystic kidney disease with a KCa3.1 blocker [25]. Moreover, Senicapoc 533 treatment reduced IL-β1, IL-6, and IL-23, and TNFα mRNA-expression levels in the 534 affected skin ( Fig 5) . These data strongly indicate that these morphological alterations 535 and the higher expression pro-proliferative cytokines as mechanistic drivers of 
